Hematopoietic cell transplantation for chronic lymphocytic leukemia

Farrukh T. Awan, Mohamed A. Kharfan-Dabaja

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


The utilization of hematopoietic cell transplantation (HCT) for the management of patients with chronic lymphocytic leukemia (CLL) has undergone substantial changes over the last decade, especially with the advent of novel therapeutic options including kinase inhibitors. The various new therapeutics including b-cell receptor (BCR; BTK and PI3K), and BCL-2 inhibitors have also demonstrated activity in patients with refractory disease and high-risk features. Given the limited benefit and substantial toxicity of autologous HCT, it is not recommended for routine use in patients with CLL. Moreover, the use of allogeneic HCT should also be limited to appropriate patients with high-risk and progressive disease on BCR or BCL-2 inhibitors. These recommendations are also likely to be modified in the future given the increasing use of combination strategies of these novel agents resulting in deeper and potentially more durable responses and the promising efficacy observed with the use of chimeric antigen receptor cell therapy.

Original languageEnglish (US)
Title of host publicationHematopoietic Cell Transplantation for Malignant Conditions
Number of pages6
ISBN (Electronic)9780323568029
ISBN (Print)9780323568036
StatePublished - Jan 1 2019
Externally publishedYes


  • Allogeneic hematopoietic cell transplantation
  • Autologous hematopoietic cell transplantation
  • B-cell receptor inhibitors
  • BCL-2 inhibitors
  • Chemoimmunotherapy
  • Chronic lymphocytic leukemia
  • Graft versus host disease
  • Hematopoietic cell transplantation
  • Kinase inhibitors
  • Nonrelapsed mortality

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Hematopoietic cell transplantation for chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this